U.S. Markets close in 5 hrs 8 mins


. Currency in USD
Add to watchlist
Full screen
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters30 minutes ago

    GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs

    GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals business. Walmsley, who took over in April, said GSK would in future allocate 80 percent of its R&D budget to respiratory and HIV/infectious diseases, along with two other potential areas of oncology and immuno-inflammation.

  • Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More
    Zacks1 hour ago

    Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More

    The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.

  • Forbes1 hour ago

    Earnings Preview: What To Expect From Starbucks On Thursday

    Starbucks is expected to report earnings of $0.55/share on $5.74 billion in revenue. Meanwhile, the so-called Whisper number is $0.56.